Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity

Journal of Rheumatology

Volumn 24, Issue 2, 1997, Pages 303-308

  Gabay, Cem ^a,f   Cakir, Necati ^b   Moral, Fusun ^c   Roux Lombard, Pascale ^a   Meyer, Olivier ^e   Dayer, Jean Michel ^a   Vischer, Thomas ^a   Yazici, Hasan ^d   Guerne, Pierre André ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SSK Hospital   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e BICHAT HOSPITAL   (France)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

acute phase protein response; interleukin 1 receptor antagonist; systemic lupus erythematosus; tumor necrosis factor soluble receptors

Indexed keywords

ACUTE PHASE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE PHASE RESPONSE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACUTE-PHASE PROTEINS; ACUTE-PHASE REACTION; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS; SPONDYLITIS, ANKYLOSING;

EID: 0031048768     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Honig S, Gorevic P, Weissmann G: C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 1977;20:1065-70.
2. Gabay C, Roux-Lombard P, De Moerloose P, Dayer J-M, Vischer T, Guerne P-A: Absence of correlation between interleukin-6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993;20:815-21.
3. Pepys MB, Lanham JG, De Beer FC: C-reactive protein in SLE. Clin Rheum Dis 1982;8:91-101.
4. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;9:1351-7.
5. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute-phase response. Biochem J 1990;265:621-36.
6. Castell JV, Gomez-Lechon MJ, David M, et al: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:231-9.
7. Gabay C, Genin B, Mentha G, Iynedjian PB, Roux-Lombard P, Guerne P-A: IL-1 receptor antagonist does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells. Clin Exp Immunol 1995;100:306-13.
8. Banks RE, Forbes MA, Storr M, et al: The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995;102:217-23.
9. Baumann H, Schendel P: Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem 1991;30:20424-7.
10. Baumann H, Wong GG: Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor. J Immunol 1989;143:1163-7.
11. Richards C, Brown TJ, Shoyab M, Baumann H, Gauldie J: Recombinant oncostatin M stimulates the production of acute phase proteins in HEp G2 cells and rat primary hepatocytes in vitro. J Immunol 1992;148:1731-6.
12. Schooltink H, Stoyan T, Roeb E, Heinrich PC, Rose-John S: Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes. FEBS Lett 1992;314:280-4.
13. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991;147:117-23.
14. Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S: Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993;13:58-67.
15. Gabay C, Singwe M, Genin B, et al: Circulating levels of interleukin-11 and leukemia inhibitory factor do not significantly participate in the production of acute-phase proteins by the liver. Clin Exp Immunol 1996;105:260-5.
16. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1211-1.
17. Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in the systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
18. Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1987;31:315-24.
19. Dougados M, van der Linden S, Juhlin R, et al: The European Spondylarthropathy Study Group preliminary criteria for the classification of Spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
20. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL: An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991;142:157-65.
21. Roux-Lombard P, Punzi L, Hasler F, et al: Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:485-9.
22. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S: Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;149:2021-7.
23. Gabay C, Silacci P, Genin B, Mentha G, Le Coultre C, Guerne P-A: Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes, Eur J Immunol 1995;25:2378-83.
24. Aderka D, Wysenbeek A, Engelmann H, et al: Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
25. Suzuki H, Takemura H, Kashiwagi H: Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Arthritis Rheum 1996;38:1055-9.
26. Gabay C, Gay-Crosier F, Roux-Lombard P, et al: Elevated serum levels of interleukin-1 receptor antagonist in polymyositisdermatomyositis: A biological marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994;37:1744-51.
27. Ganapathi MK, Rzewnicki D, Samols D, Jiang S-L, Kushner I: Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in HEp 3B cells. J Immunol 1991;147:1261-5.
28. Damtew B, Rzewnicki D, Lozanski G, Kushner I: IL-1 receptor antagonist affects the plasma protein response of HEp B3 cells to conditioned medium from lipopolysaccharide-stimulated monocytes. J Immunol 1993;150:4001-7.
29. Granowitz EV, Santos AA, Poutsiaka DD, et al: Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet 1991;338:1423-4.
30. Aderka D, Engelmann H, Hornik V, et al: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991;51:5602-7.
31. Barrera P, Boerbooms AMT, Janssen EM, et al: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993;36:1070-5.
32. Gattorno M, Picco P, Buoncompagni A, et al: Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996;55:243-7.
33. Prieur A-M, Kaufmann M-T, Griscelli C, Dayer J-M: Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987;2:1240-2.
34. De Benedetti F, Pignatti P, Massa M, Sartirana P, Ravelli A, Martini A: Circulating levels of interleukin Iß and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1995;13:779-84.
35. Ishida H, Muchumuel T, Sakaguchi S, Andrade S, Menon S, Howard M: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:395-410.
36. Takeno M, Hirayama K, Sakane T: The pathogenic role of Th2 cells in systemic lupus erythematosus (abstr). Arthritis Rheum 1992;(suppl)35:S159.
37. Needleman BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and Interferon gamma levels in sera from patients with sclerodermu. Arthritis Rheum 1992;35:67-72.
38. Vannier E, Miller LC, Dinarello CA: Coordinated antiinflammatory effects of interleukin-4: Interleukin 4 suppresses interleukin 1 production hut up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992;89:4076-80.
39. De Waal Malefyt R, Figdor CG, Huijbens R, et al: Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFNγ or IL-10. J Immunol 1993;151:6370-81.
40. Joyce DA, Steer JH: IL-4, IL-10 and IFN-γ have distinct, but interacting, effects of differentiation-induced changes in TNF-α and receptor release by cultured human monocytes. Cytokine 1996;8:49-57.
41. Loyer P, Ilyin G, Razzak ZA, et al: Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 1993;336:215-20.
42. Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.